Revenues stood at 2206 crore, reflecting a ~33% YoY growth. The CDMO business grew ~86% YoY, reaching 875 crore. The growth in Generic Formulations was at 31% to 677 crore. Generic API grew 1% YoY to 625 crore and the Laurus Bio de-grew ~38% YoY to 29 crore. EBITDA stood at 750 crore with a margin of 34%, marking a significant improvement of 962 basis points YoY mainly due to 314 bps YoY improvement in GPM to 63%. PAT stood 437 crore, driven by a favourable product mix and improving operational leverage....